California 2026 Psychedelics Ballot Measure: Explainer

California advocates are preparing a 2026 statewide ballot measure to legalize psilocybin and MDMA. The push is the latest move in a four-year campaign that has stalled twice in the legislature — Governor Newsom vetoed SB 58 in October 2023, and Sen. Scott Wiener's broader SB 1012 failed in the Senate Appropriations Committee in 2024.

Why a ballot measure now

The 2026 ballot push is Plan B. Wiener's office has been clear that legislative routes have been exhausted for the moment. Direct democracy has worked before: Colorado's Proposition 122 passed in 2022, and Oregon's Measure 109 passed in 2020. Both were ballot initiatives, not legislative bills.

California's signature-gathering threshold for a statutory ballot initiative is roughly 546,000 valid signatures. For a constitutional amendment, the bar is closer to 875,000. Most observers expect the coalition to pursue the statutory route to keep signature requirements manageable.

What is on the table

The exact scope is not finalized. Coalition members are debating whether the measure should cover therapeutic access only, or include broader personal-use decriminalization. The two leading approaches:

• Therapeutic-only model. Mirrors Oregon Measure 109 and Colorado's healing centers. Adults could legally use psilocybin and possibly MDMA under licensed facilitator supervision. No retail sale, no possession outside a licensed setting.
• Decriminalization-plus model. Removes criminal penalties for personal possession and use of natural psychedelics, similar to Colorado's broader Prop 122. May or may not include synthetic compounds like MDMA.

The coalition includes Heroic Hearts Project, the Veterans Mental Health Leadership Coalition, and a number of clinicians and bioethicists. Industry-funded groups (with money behind Compass Pathways and atai adjacent operators) are also weighing in, often favoring the therapeutic-only model.

The SB 751 track running in parallel

SB 751, introduced by Sen. Josh Becker and co-sponsored by nine bipartisan lawmakers, is the live legislative track in 2026. The bill creates a Veterans and First Responders Research Pilot Program focused on psilocybin services in up to five counties.

SB 751 does not legalize psilocybin. It creates a narrowly tailored exception to support federally compliant research for veterans and inactive first responders facing PTSD, end-of-life distress, or related conditions. The bill is closer in spirit to Texas's $50 million ibogaine research investment than to a full decriminalization push.

If SB 751 passes and the 2026 ballot measure also qualifies and passes, California would have two parallel psychedelic frameworks: a narrow research pilot plus a broader legal-access program.

The 2023 veto that shaped the 2026 strategy

Governor Newsom's October 2023 veto of SB 58 is the policy event that shaped this strategy. SB 58 would have decriminalized personal possession of psilocybin, psilocyn, DMT, ibogaine, and mescaline. Newsom vetoed it on the grounds that the bill lacked a regulated therapeutic framework — possession without access, in his framing, was the wrong sequence.

The 2024 Wiener bill (SB 1012) tried to add a regulated framework on top of decriminalization. It failed in Appropriations on cost grounds, not policy grounds. The 2026 ballot measure is meant to respond to both critiques: a regulated framework, funded by participant fees rather than the General Fund.

Federal context: the Trump EO does not preempt

The April 18, 2026 federal psychedelics executive order does not change anything about a California ballot measure. State law and federal law operate on different tracks. Federal Schedule I status continues to apply to psilocybin and MDMA, regardless of state regulation.

We covered the federal order in our Trump psychedelics executive order explainer. The short version: federal review is accelerating but rescheduling is not.

What to watch between now and November 2026

1. Title and summary filing. The Attorney General assigns a title and summary before signature gathering begins. Expect filing in summer or early fall 2026.
2. Signature drive. Coalitions usually need about 6 months to gather enough valid signatures. Watch for the launch.
3. Funding disclosures. California requires committee filings. Compass Pathways, atai, MAPS, Heroic Hearts, and Wiener's own committees are likely funders to track.
4. Veterans-group endorsements. The American Legion, VFW, and Iraq and Afghanistan Veterans of America have already signaled support for veterans-specific access. A broader push may turn on whether they endorse the ballot measure.
5. SB 751 votes. Whether the narrower veterans pilot makes it to Newsom's desk in 2026 will shape ballot-measure messaging — coalition can argue "incremental did not work" if SB 751 dies, or "legislators left work undone" if SB 751 passes but only covers a few counties.

If the 2026 ballot measure passes

California would join Oregon, Colorado, and New Mexico as the fourth state with a state-legal pathway. The market scale is significant: California has ~39 million residents, more than the combined populations of Oregon, Colorado, and New Mexico.

Implementation would take 18–36 months. Oregon's Measure 109 took roughly two years between voter approval (2020) and the first licensed service center opening (2023). Colorado is on a similar timeline.

For full California legal context, see our California psilocybin legal status page and the national US psychedelic legal map.

The bottom line

California's 2026 psychedelics ballot measure is the most consequential state-level psychedelic policy event of the year. The legislative track has stalled twice; ballot initiatives have a stronger track record. The open questions are scope (therapeutic-only or broader) and funder alignment between veterans groups, clinicians, and industry.

We will update this briefing as the title and summary are filed and the signature drive launches.